Genomic Microarray

GenoSensor™ Array 300 second-generation genomic microarray for the GenoSensor System enables screening for abnormal gene amplifications and deletions with the sensitivity to detect single gene-copy change in a variety of specimens. The system simultaneously screens for gene copy number changes in 287 targets spotted in triplicate, thus permitting the screening of pronto-oncogenes, tumor suppressor genes, microdeletion syndrome gene regions and subtelomeric regions. Redundancy of important gene target areas such as telomeres and those associated with microdeletion syndromes acts as an intra-assay control. Clone verification has been accomplished by confirming each clone on the microarray with fluorescence in situ hybridization (FISH) mapping and PCR with gene-specific primers. The array system aids in prenatal and postnatal genetic research including screening for genetic aberrations leading to idiopathic mental retardation. Prenatal and postnatal microarray targets include microdeletion regions, important X/Y chromosome targets, aneusomy and aneuploidy of all chromosomes and telomeres. Within cancer research, the system is intended to help provide a better understanding of the genetic basis of diseases such as cancer, whether certain cancerous tumors will be more aggressive than others, what treatments will be the most effective and those that may be ineffective. Cancer targets include proto-oncogenes from the proprietary AmpliOnc(tm) I chip, additional proto-oncogenes not currently on AmpliOnc I, and tumor suppressor genes.